Abstract
Objectives Determine durability of protection by the three currently available COVID-19 vaccines in the United States (US) following primary vaccination against breakthrough infections, hospitalizations, and intensive care unit (ICU) admissions.
Methods Using claims and laboratory data covering 168 million lives, we conducted a matched case-control study with fully vaccinated individuals between January 1 and September 7, 2021. Odds ratios (OR) for developing outcomes in months two through six following full vaccination were estimated relative to the first month after full vaccination for each vaccine separately.
Results Evidence of waning protection against infections started in month 2 from vaccination for both BNT162b2 (OR [95% CI] in month 6+, 2.93 [2.72, 3.15]) and mRNA-1273 (OR [95% CI] in month 6+, 2.76 [2.51, 3.04]), and in month 4 for Ad26.COV2.S (OR [95% CI] in month 5+, 1.31 [1.18, 1.47]). Evidence of waning protection against hospitalization started in month 2 for BNT162b2 (OR [95% CI], 3.97 [3.26, 4.83] in month 6+) and in month 3 for mRNA-1273 (OR 95% CI, 1.66 [1.26, 2.19] in month 6+). There was no evidence of waning protection against hospitalization for Ad26.COV2.S (OR [95% CI], 1.25 [0.86, 1.80] in month 5+). No waning of protection was observed at any time for ICU admissions for all three vaccines.
Conclusions Following primary vaccination, all three vaccines showed strong and durable protection against ICU admissions. Ad26.COV2.S showed a more durable level of protection against breakthrough infections and hospitalizations in line with published evidence of its durable antibody and cellular immune response, although its Vaccine Effectiveness (VE) at baseline after a single-dose is lower than that for the two-dose mRNA vaccines. Additional studies are needed to understand durability following homologous or heterologous boosters.
Competing Interest Statement
All authors with the exception of Dr. Schneeweiss are employees of Janssen R&D the manufacturer of Ad26.COV2.S.
Dr. Schneeweiss is participating in investigator-initiated grants to the Brigham and Womens Hospital from Boehringer Ingelheim unrelated to the topic of this study. He is a consultant to Aetion Inc. which has multiple research collaborations with Janssen R&D.
Funding Statement
This work was funded by Janssen Research & Development.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The collection and analysis of these data did not qualify as human subjects research under the Common Rule and were not subject to institutional review board assessment. The New England institutional review board approved this exemption (no.1-9757-1). Upon reasonable request, researchers may get access to the data and analytics infrastructure for prespecified collaborative analyses.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding This work was funded by Janssen Research & Development.
Conflicts of Interest Dr. Zheutlin, Dr. Ott, Dr. Sun, Dr. Zemlianskaia, Dr. Rubel, Ms. Hayden, Dr. Neri, Dr. Kamath, Dr. Khan and Dr. Sarsour are employees of Janssen R&D, the manufacturer of Ad26.COV2.S.
Dr. Schneeweiss is participating in investigator-initiated grants to the Brigham and Women’s Hospital from Boehringer Ingelheim unrelated to the topic of this study. He is a consultant to Aetion Inc. of which he owns equity. He did not receive consultancy fees from Janssen before, during, or after this study was conducted. His interests were declared, reviewed, and approved by the Brigham and Women’s Hospital in accordance with their institutional compliance policies.
Data Availability
Upon reasonable request, researchers may get access to the data and analytics infrastructure for prespecified collaborative analyses.
